5 completed, 2 unknown, 1 withdrawn. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Unknown 2, Withdrawn 1 |
| Phase 2 | 2 | Unknown 1, Withdrawn 1 |
Follow pramlintide: new trials by email Literature Review of pramlintide trials Research Report on pramlintide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tailoring Obesity Treatment Trial Pramlintide Acetate 1 MG/ML, Semaglutide Pen Injector, Sodium Chloride 0.9% Inj - Obesity, Appetite Regulation | Phase 2 / Phase 3 | Withdrawn | Esbjerg Hospital - University Hospital of Southern Denmark | 2025-04-01 | 2026-04-17 | |
| A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes Pramlintide, Lyumjev, Automated Insulin Delivery (AID) system - type1diabetes, Diabetes Mellitus, Type 1 | Phase 2 / Phase 3 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 30 | 2023-11-30 | 2024-04-18 |
| Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus Pramlintide - Type 2 Diabetes Mellitus | Phase 3 | Unknown | Cheryl Rosenfeld, DO | 40 | 2010-05-01 | 2011-10-14 |
| The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes Pramlintide - Type 1 Diabetes | Phase 3 | Completed | Baylor College of Medicine | 20 | 2003-10-01 | 2016-07-14 |
| Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus pramlintide acetate - Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 3 | Completed | AstraZeneca | 400 | 2003-04-01 | 2015-05-21 |
| Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus pramlintide acetate - Diabetes Mellitus, Type 1 | Phase 3 | Completed | AstraZeneca | 190 | 2002-11-01 | 2015-09-23 |
| The Role of Amylin and Glucagon in T1DM Pramlintide and glucagon - Type 1 Diabetes | Phase 3 | Completed | Baylor College of Medicine | 30 | 2002-07-01 | 2016-07-14 |
| Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control Pramlintide acetate, Placebo - Diabetes Mellitus, Type 1 | Phase 3 | Completed | AstraZeneca | 296 | 2002-04-01 | 2015-09-23 |
Diabetes Mellitus, Type 1 (6) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Hyperglycemia (2) · Hypoglycemia (2) · Insulin Resistance (1) · Obesity (1) · Prediabetic State (1)
AstraZeneca (3) · Baylor College of Medicine (2) · Cheryl Rosenfeld, DO (1) · Esbjerg Hospital - University Hospital of Southern Denmark (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1)
United States (6) · Canada (1) · Denmark (1)
Lisa Porter, MD (2) · Rubina Heptulla, MD (2) · Ahmad Haidar, Ph.D. (1) · Alan Schorr, DO (1) · Cheryl Rosenfeld, DO (1) · Claus Bogh Juhl, MD, phd, professor (1) · Jeffrey Rothman, MD (1) · Laurent Legault, M.D. (1) · Melissa-Rosina Pasqua, M.D. (1) · Michael Tsoukas, M.D. (1) · Michael Vallis, Ph.D. (1) · Natasha Garfield, M.D. (1)
PMID 23748514, PMID 15793249, PMID 17109671, PMID 17425446, PMID 18715216